



(51) International Patent Classification:

C07D 207/09 (2006.01) **C07D 413/12** (2006.01)
C07D 207/10 (2006.01) **C07D 413/14** (2006.01)
C07D 207/12 (2006.01) **C07D 417/12** (2006.01)
C07D 211/26 (2006.01) **C07D 417/14** (2006.01)
C07D 241/04 (2006.01) **A61K 31/4025** (2006.01)
C07D 265/30 (2006.01) **A61K 31/4523** (2006.01)
C07D 401/04 (2006.01) **A61K 31/5355** (2006.01)
C07D 401/12 (2006.01)

CH-4410 Liestal (CH). **NORCROSS, Roger** [GB/CH];
 Rheinfelderstrasse 2, CH-4305 Olsberg (CH).
PFLIEGER, Philippe [FR/FR]; 1, rue du Vignoble,
 F-68130 Schwoben (FR).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124,
 CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
 SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2010/070045

(22) International Filing Date:

17 December 2010 (17.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09180504.4 22 December 2009 (22.12.2009) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacher-
 strasse 124, CH-4070 Basel (CH).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **GROEBKE ZBINDEN, Katrin** [CH/CH]; Laubibergstrasse 61,

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: SUBSTITUTED BENZAMIDE DERIVATIVES



(57) Abstract: The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R¹ is -(CH₂)_n-(O)_o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH₂)_p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R² is CF₃, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF₃, OCF₃, OCH₂CF₃, OCH₂-cycloalkyl, OCH₂C(CH₂OH)(CH₂Cl)(CH₃), S-lower alkyl, lower alkoxy, CH₂-lower alkoxy, lower alkynyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O-CH₂-phenyl, phenyl or -CH₂-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH₂-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR', -CH₂NH-, -(CHR')_q-O-, -O-(CHR')_q- or -(CH₂)₂-; Y is a bond or -CH₂- R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF₃, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

WO 2011/076678 A1



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**
GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*